CA3 Antibody (N-term) Blocking Peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | P07451 |
---|---|
Clone Names | 80411146 |
Gene ID | 761 |
---|---|
Other Names | Carbonic anhydrase 3, Carbonate dehydratase III, Carbonic anhydrase III, CA-III, CA3 |
Target/Specificity | The synthetic peptide sequence used to generate the antibody AP7633a was selected from the N-term region of human CA3. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay. |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | CA3 {ECO:0000303|PubMed:9651514, ECO:0000312|HGNC:HGNC:1374} |
---|---|
Function | Reversible hydration of carbon dioxide. |
Cellular Location | Cytoplasm. |
Tissue Location | Muscle specific. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Carbonic anhydrase III (CAIII) is a member of carbonic anhydrase isozymes. These carbonic anhydrases are a class of metalloenzymes that catalyze the reversible hydration of carbon dioxide and are differentially expressed in a number of cell types. The expression of the CA3 gene is strictly tissue specific and present at high levels in skeletal muscle and much lower levels in cardiac and smooth muscle. A proportion of carriers of Duchenne muscle dystrophy have a higher CA3 level than normal.
References
Du,A.L., Autoimmunity 42 (3), 209-215 (2009)Dai,H.Y., Mol. Carcinog. 47 (12), 956-963 (2008)Gailly,P., Kidney Int. 74 (1), 52-61 (2008)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.